Dec 05, 2019
Cancer Treatment Centers of America Continues Pioneering Efforts in Immuno-Oncology; Doses First Patient in Novel Immunotherapy Clinical Trial
Nov 06, 2019
Oncopeptides to Highlight Data From Melflufen Clinical Program in Multiple Myeloma and AL Amyloidosis in Six Presentations at ASH Annual Meeting 2019
Nov 06, 2019
Kleo Pharmaceuticals Presents Preclinical Data Supporting Development of its CD38-ARM(TM), a Novel Immuno-therapeutic, at American Society of Hematology (ASH) Annual Meeting
Sep 26, 2019
Janssen Announces U.S. FDA Approval of DARZALEX® (daratumumab) Combination Regimen for Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma
Sep 26, 2019
Patient Recruitment in the Pivotal Phase 2-Study HORIZON Completed
Sep 15, 2019
New Interim Data in RRMM Patients With Extramedullary Disease from the Pivotal Phase 2 Horizon-study Presented at International Myeloma Workshop
Aug 16, 2019
Oncopeptides Announces Acceptance of Data for Presentation at International Myeloma Workshop, September 12-15
Jul 19, 2019
Halozyme Announces Janssen Submits Extension Application To European Medicines Agency For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology
Jul 12, 2019
Halozyme Announces Janssen Submits BLA To FDA For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology
Jul 12, 2019
Janssen Submits Application to U.S. FDA Seeking Approval of New DARZALEX® (daratumumab) Subcutaneous Formulation
Jul 03, 2019
FDA approves new treatment for refractory multiple myeloma
Jun 26, 2019
Actinium Poster Detailing Actinium-225 Labeled Daratumumab Selected in Top Poster Award Competition at 2019 Society of Nuclear Medicine and Molecular Imaging Annual Meeting
Jun 20, 2019
Actinium's Portfolio of Antibody Radiation-Conjugates to be Highlighted in Two Oral and Two Poster Presentations at the 2019 Society of Nuclear Medicine and Molecular Imaging Annual Meeting
Jun 19, 2019
World Multiple Myeloma Disease Coverage Forecast and Market 2018-2024: Leading Multiple Myeloma Drugs will Soon Face Generic Competition
Jun 16, 2019
New Data Presented from Oncopeptides' Pivotal Phase 2 HORIZON Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma at 24th EHA Congress
Jun 14, 2019
New Data Presented at 24th EHA Congress From Oncopeptides' Phase 1/2 ANCHOR Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma (RRMM)
Jun 02, 2019
DARZALEX® (daratumumab) Investigational Study Shows Increased Depth of Response and Longer Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Who are Eligible for a Transplant
Jun 02, 2019
Phase 3 COLUMBA Study Investigating a Subcutaneous Formulation of DARZALEX® (daratumumab) Showed Non-Inferiority to Intravenous Administration in Patients with Relapsed/Refractory Multiple Myeloma
May 29, 2019
DARZALEX® (daratumumab) Phase 3 MAIA Study Results, Published in The New England Journal of Medicine, Show Combination Therapy Increases Progression-Free Survival in Newly Diagnosed Patients with Multiple Myeloma Who are Transplant Ineligible
May 16, 2019
Oncopeptides Announces Acceptance of Four Abstracts Highlighting Melflufen Clinical Programs for Presentation at 24th EHA Congress in June 2019